Business Wire

NY-UNIFRAX

Share
SiFAB™ by Unifrax Will Be Featured at The Battery Show North America

Unifrax , a leading manufacturer of high-performance specialty materials will feature their latest innovation, SiFAB™ Silicon Fiber Anode Battery Technology , at next week’s Battery Show in Novi, Michigan. Unifrax launched SiFAB earlier this year, and will feature the new silicon fiber technology during a technical presentation and exhibit during this year’s The Battery Show and Electric & Hybrid Vehicle Technology Expo at Suburban Collection Showplace, September 14-16.

Bruce Zoitos, senior scientist and manager, materials research, Unifrax, will present data obtained following advanced testing of SiFAB, which has demonstrated promising performance in multiple battery systems. SiFAB, uniquely structured for high-capacity performance, enables significantly higher energy density in lithium-ion battery systems and has successfully been tested with incremental Si loadings of greater than 40 percent. Zoitos will present these findings during a technical session on Wednesday, September 15 at 2:30 p.m. in the Crystal Room.

“Lithium-ion batteries are playing a pivotal role in our everyday life,” said Zoitos. "Along with greater energy density, SiFAB will provide faster charges and longer battery life for applications including electric vehicles, portable electronics, power tools, energy grid storage, and aerospace. With SiFAB, our recent testing shows our technology can provide a drop-in solution that can be incorporated as early as 2022, enabling better and longer-performing applications.”

The data, collected in part by Wildcat Discovery Technologies, and the Battery Innovation Center, support SiFAB’s promising performance with significantly higher capacity and fast charging capability in various electrode formulations.

According to advanced testing performed in 2021, SiFAB has demonstrated:

  • Reversible capacity greater than 1,000 mAh/g enabling gravimetric energy density improvement over graphite up to 20 percent
  • Robust performance in various electrode formulations which allows design flexibility to cell makers and OEMs
  • Proven high-rate charge and discharge performance up to 4C
  • Proven high temperature performance at 45°C
  • Stable cycling with high Si loadings and minimal volume expansion. Cycling of these batteries is ongoing
  • SiFAB drops into existing manufacturing process; SiFAB has been successfully applied in roll-to-roll processes in standard manufacturing scenarios

“After working with reputable battery labs and partners to test SiFAB, we’re excited to share SiFAB testing results at The Battery Show next week,” said Chad Cannan, senior vice president of research and development, Unifrax. “Our data shows SiFAB delivers strong performance in realistic cell conditions and real-world applications. With SiFAB’s promising performance, and Unifrax’s ability to scale up manufacturing with our first SiFAB manufacturing line being built at our Indiana manufacturing site now, our plan is on track for producing tens of metric tons in early 2022 with hundreds of metric tons capacity planned for 2023, making SiFAB a reality for customers,” said Cannan.

In addition to the SiFAB technical session with Bruce Zoitos, Unifrax will be available at booth #1431 during the 2021 Battery Show September 14-16, to discuss SiFAB technology with interested attendees.

To learn more about SiFAB, and to request a sample, visit www.sifab.com .

About Unifrax

Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn and Facebook .

About Clearlake

Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $39 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye